<DOC>
	<DOCNO>NCT01973309</DOCNO>
	<brief_summary>This open-label Phase 1b dose-escalation study ass safety , tolerability , PK vantictumab combine paclitaxel .</brief_summary>
	<brief_title>A Study Vantictumab ( OMP-18R5 ) Combination With Paclitaxel Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>Once maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) determine , 10 patient may enrol cohort-expansion phase well characterize safety , tolerability PK vantictumab combine paclitaxel . Up approximately 34 patient may enrol study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥18 year Histologically document adenocarcinoma breast locally recurrent metastatic disease Patients breast cancer overexpressing HER2 eligible . Availability tumor tissue , either archival FFPE obtain study entry fresh biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 All acute treatmentrelated toxicity prior therapy must resolve Grade ≤ 1 prior study entry Adequate hematologic endorgan function Evaluable measurable disease per RECIST v1.1 For woman childbearing potential , agreement use two effective form contraception Known significant dose delay prior treatment taxane due drugrelated toxicity Prior treatment two regimen systemic cytotoxic chemotherapy locally recurrent metastatic disease Treatment anticancer therapy within 3 week prior initiation study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Locally Recurrent</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>